Trials / Completed
CompletedNCT02689245
Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Institute of Liver and Biliary Sciences, India · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Data for stool microbiome will be collected for all the chronic hepatitis B subjects (pre cirrhotic,compensated,decompensated and reactivation). All the in and out patient with Hepatitis B reactivation will be recruited and randomized into two arms. Group 1 Tenofovir Group 2 Tenofovir with FMT (Fecal Microbiota Transplant). Tenofovir would be given 300 mg once daily FMT through NJ (Naso-Jejunal) tube for 7 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir | |
| DRUG | Fecal Microbiota Transplantation (FMT) |
Timeline
- Start date
- 2016-02-26
- Primary completion
- 2018-03-13
- Completion
- 2018-03-13
- First posted
- 2016-02-23
- Last updated
- 2018-11-23
Locations
1 site across 1 country: India
Source: ClinicalTrials.gov record NCT02689245. Inclusion in this directory is not an endorsement.